Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by CenterBook Partners LP

CenterBook Partners LP grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 57,223 shares of the biopharmaceutical company’s stock after acquiring an additional 5,632 shares during the period. Regeneron Pharmaceuticals accounts for about 1.6% of CenterBook Partners LP’s investment portfolio, making the stock its 6th biggest position. CenterBook Partners LP owned approximately 0.05% of Regeneron Pharmaceuticals worth $32,175,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. CoreCap Advisors LLC raised its position in Regeneron Pharmaceuticals by 9.2% in the 3rd quarter. CoreCap Advisors LLC now owns 238 shares of the biopharmaceutical company’s stock worth $134,000 after purchasing an additional 20 shares during the last quarter. Strait & Sound Wealth Management LLC boosted its position in Regeneron Pharmaceuticals by 3.5% in the 3rd quarter. Strait & Sound Wealth Management LLC now owns 628 shares of the biopharmaceutical company’s stock valued at $353,000 after buying an additional 21 shares during the last quarter. Parkside Financial Bank & Trust increased its stake in shares of Regeneron Pharmaceuticals by 14.8% in the 3rd quarter. Parkside Financial Bank & Trust now owns 163 shares of the biopharmaceutical company’s stock valued at $92,000 after buying an additional 21 shares during the period. Independence Bank of Kentucky raised its position in shares of Regeneron Pharmaceuticals by 7.7% during the third quarter. Independence Bank of Kentucky now owns 308 shares of the biopharmaceutical company’s stock worth $173,000 after acquiring an additional 22 shares during the last quarter. Finally, Redwood Wealth Management Group LLC raised its position in shares of Regeneron Pharmaceuticals by 4.8% during the second quarter. Redwood Wealth Management Group LLC now owns 506 shares of the biopharmaceutical company’s stock worth $266,000 after acquiring an additional 23 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently issued reports on REGN shares. Zacks Research cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. Canaccord Genuity Group upped their target price on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a research report on Thursday, December 4th. UBS Group lifted their price target on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. HSBC upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 24th. Finally, Guggenheim raised their price objective on shares of Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $793.81.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, SVP Jason Pitofsky sold 2,036 shares of the business’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the sale, the senior vice president directly owned 4,272 shares of the company’s stock, valued at approximately $3,325,837.44. The trade was a 32.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 3,636 shares of company stock valued at $2,862,920. 7.02% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $793.53 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. The firm has a market cap of $83.89 billion, a PE ratio of 19.09, a P/E/G ratio of 2.16 and a beta of 0.40. The business’s 50-day moving average price is $766.18 and its two-hundred day moving average price is $670.05.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the firm posted $12.07 earnings per share. Regeneron Pharmaceuticals’s revenue was up 2.5% compared to the same quarter last year. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be issued a dividend of $0.94 per share. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date is Friday, February 20th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is 8.47%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.